#Australia #Melbourne #CE Mark #4DMedical #CTVQ

4DMedical Achieves CE Mark for Innovative CTVQ™ Technology

In a significant advancement for lung imaging, 4DMedical Limited, a leading entity based in Melbourne, Australia, has announced that its cutting-edge imaging technology, CTVQ™, has received the CE Mark for commercial use across the European Union. This accreditation is set to facilitate 4DMedical's entry into one of the world’s largest markets for medical imaging, especially in the realm of respiratory medicine.

Overview of CTVQ™ Technology

CTVQ™ stands for Contrast-Free Ventilation-Perfusion Quantification. This trailblazing technology uniquely combines the structural clarity of traditional CT scans with functional insights into lung performance derived from non-contrast CT images. This innovation allows clinicians to obtain quantitative evaluations of regional lung function without the use of radioactive tracers, marking an important leap forward in the field.

The clinical significance of CTVQ™ is profound, especially as lung diseases typically present as functional impairments characterized by ventilation and perfusion abnormalities. Traditional imaging modalities often focus solely on structural aspects, leaving a crucial gap in functional assessments. CTVQ™, however, provides ventilation and perfusion maps, enabling healthcare professionals to visualize and quantify lung functionality alongside anatomical details, significantly enhancing diagnostic accuracy.

European Market Potential

The EU represents a substantial opportunity for modern cardiothoracic imaging, with a population exceeding 450 million and a well-established infrastructure for medical imaging. There exists a vast number of installed CT scanners in hospitals across Europe, which positions the region favorably for the adoption of CT-based functional lung imaging technologies. 4DMedical estimates that approximately 400,000 nuclear VQ scans are conducted annually in the EU, further underscoring the unmet clinical needs that CTVQ™ aims to address.

In tandem with the CE certification announcement, 4DMedical has also secured commitments from institutional investors for an impressive AUD 83 million private placement. This additional funding will primarily support the company’s growth initiatives, including its planned expansion into the European market.

The CEO and founder of 4DMedical, Andreas Fouras, emphasized the importance of this CE Mark achievement, describing it as a milestone that opens up one of the largest and most demanding health markets in the world. He noted that with the FDA approval already in hand, the company is poised to rapidly commercialize CTVQ™ across both the U.S. and EU markets.

Existing Adoption and Future Plans

The CTVQ™ technology has already seen early adoption within six major academic medical centers in the United States, including well-respected institutions such as Stanford, Cleveland Clinic, and Mayo Clinic. 4DMedical claims that this interest from prestigious U.S. organizations illustrates a definitive demand for CTVQ™ among leading radiology and pulmonary teams and sets a solid foundation for the expansion in Europe.

Moving forward, 4DMedical aims to broaden its commercial presence throughout Europe, collaborating with top-tier hospitals and clinicians for the introduction, evaluation, and ongoing research pertaining to CTVQ™. This initiative will not only facilitate the implementation of CTVQ™ technology but also contribute to significant enhancements in lung disease diagnostics and treatment planning, ultimately aiming for improved patient outcomes.

Conclusion

4DMedical's CTVQ™ signifies a groundbreaking step in respiratory imaging technology, combining the precision of CT imaging with real-time functional assessments. The company's strategy to address the clinical demands of lung-related ailments through innovative imaging underscores its commitment to advancing healthcare technology globally. As the CE certification propels the technology into the European market, the future looks promising not only for 4DMedical but also for clinicians and patients who stand to benefit from enhanced diagnostic capabilities in lung health.

For more details about 4DMedical and CTVQ™, visit www.4dmedical.com.